ABSTRACT
Medical records for 67 cats with histologically confirmed mammary gland adenocarcinomas treated with adjunctive doxorubicin from June 1994 through December 2002 were reviewed. Data were examined to evaluate factors influencing disease-free interval (DFI) and survival time. The Kaplan-Meier median survival time of cats that received surgery and doxorubicin was 448 days. The Kaplan-Meier median DFI was 255 days. Significant univariate prognostic factors for DFI included histological subtype, completion of initial chemotherapy, development of metastatic disease, and location of metastatic disease. Significant univariate prognostic factors for survival included tumor volume, the development of metastatic disease, and location of metastatic disease.
Subject(s)
Adenocarcinoma/veterinary , Antibiotics, Antineoplastic/therapeutic use , Cat Diseases/drug therapy , Doxorubicin/therapeutic use , Mammary Neoplasms, Animal/drug therapy , Adenocarcinoma/drug therapy , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Animals , Cat Diseases/mortality , Cat Diseases/pathology , Cats , Disease-Free Survival , Female , Kaplan-Meier Estimate , Male , Mammary Neoplasms, Animal/mortality , Mammary Neoplasms, Animal/pathology , Neoplasm Metastasis , Neoplasm Staging/veterinary , Prognosis , Retrospective Studies , Treatment OutcomeABSTRACT
The mammary glands are frequent locations for the development of tumors. In the dog and cat, early detection and rapid therapy are necessary to prevent both local and distant metastasis. In the dog, this disease can have a range of biologic behaviors, whereas in the cat it is almost always an extremely aggressive disease. Treatment options depend on tumor staging and can include surgery, radiation therapy, chemotherapy, or a combination. As we become better at early diagnosis and are able to implement aggressive therapy, we are becoming more and more successful in the treatment of this disease. In the following article, we will discuss current thoughts surrounding the diagnosis and treatment options for both canine and feline mammary gland tumors.
Subject(s)
Cat Diseases/therapy , Dog Diseases/therapy , Mammary Neoplasms, Animal/therapy , Animals , Cat Diseases/drug therapy , Cat Diseases/pathology , Cat Diseases/radiotherapy , Cat Diseases/surgery , Cats , Combined Modality Therapy/veterinary , Dog Diseases/drug therapy , Dog Diseases/pathology , Dog Diseases/radiotherapy , Dog Diseases/surgery , Dogs , Female , Mammary Neoplasms, Animal/drug therapy , Mammary Neoplasms, Animal/pathology , Mammary Neoplasms, Animal/radiotherapy , Mammary Neoplasms, Animal/surgery , Veterinary MedicineABSTRACT
In the last decade, there has been a great deal of information surrounding the etiology, diagnosis, and treatment of feline vaccine-associated sarcomas. The presence of a mass in areas used for subcutaneous or intramuscular injections should alert the clinician to the possibility of a vaccine-associated sarcoma. Early detection and subsequent treatment is paramount to limit local invasion and distant metastasis. The current data are suggesting that a team approach with multi-modality therapy is the appropriate way to address this disease. In the following article, we will discuss the history/incidence, pathology, diagnosis, and current treatment options, which include a combination of surgery, radiation, and chemotherapy for vaccine-associated sarcomas.
